News about "licensing agreement"

Transgene, NEC Bio B.V. Sign Licensing Deal to Advance AI-Driven Cancer Vaccine

Transgene's Agreement wirh NEC Bio B.V. to accelerate development of TG4050, a personalised neoantigen immunotherapy for head and neck cancer, combining viral vector technology with AI-based prediction.

Licensing Agreement | 07/04/2026 | By News Bureau

Samsung Bioepis and Epis NexLab Partner G2GBIO to Develop Long-Acting Semaglutide

Samsung Bioepis and Epis NexLab have signed a research collaboration and licensing agreement with G2GBIO to develop novel assets, including long-acting semaglutide, using G2GBIO’s proprietary microsphere drug delivery technology.

Licensing Agreement | 16/03/2026 | By News Bureau |  106

Antengene Licenses ATG-201 to UCB in Deal Worth Up to USD 1.1 Billion for Autoimmune Disease Therapy

Antengene grants UCB exclusive global rights to develop and commercialise ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases, in a deal worth over USD 1.1 billion in milestones and royalties.

Licensing Agreement | 06/03/2026 | By News Bureau |  158

Angelini Pharma, Quiver Bioscience Ink USD 120 Million Pact to Develop Genetic Epilepsy Therapies

Angelini Pharma and Quiver Bioscience have signed a multi-year collaboration to develop novel therapies for genetic epilepsies, combining AI-driven discovery tools with epilepsy expertise in a deal worth up to USD 120 million.

Licensing Agreement | 25/02/2026 | By News Bureau |  154

THX Pharma and Biocodex Sign Licensing Deal for Rare Disease Drug Candidates

Biocodex secures global rights to Batten-1 and North American rights to TX01 from THX Pharma in a deal worth up to Euro 173 million to advance treatments for juvenile Batten disease, Gaucher disease and Niemann-Pick type C.

Licensing Agreement | 13/02/2026 | By News Bureau |  181

Genethon Partners with AskBio on Pompe Gene Therapy

The licensing deal enables AskBio to advance the clinical development of Genethon’s investigational gene therapy for Pompe disease through an industry partnership.

Licensing Agreement | 15/01/2026 | By News Bureau |  123

Valneva and Serum Institute End Chikungunya Vaccine Licensing Deal

Valneva SE and the Serum Institute of India have mutually agreed to discontinue their licensing agreement for Valneva’s single-shot chikungunya vaccine, bringing the collaboration to a close by mutual consent.

Licensing Agreement | 01/01/2026 | By News Bureau |  111

Biofabri and Bharat Biotech Sign Technology Transfer Deal for MTBVAC

Biofabri and Bharat Biotech have entered into a technology transfer agreement to enable end-to-end manufacturing of the MTBVAC tuberculosis vaccine candidate, supporting global efforts to expand access to new TB prevention options, particularly in high-burden, low- and middle-income countries.

Licensing Agreement | 24/12/2025 | By News Bureau |  187

Glenmark Secures Exclusive Multi-Region Rights to Aumolertinib from Hansoh Pharma

Glenmark has entered into an exclusive licensing agreement with Hansoh Pharma to commercialise aumolertinib, a third-generation EGFR-TKI approved by the MHRA and China’s NMPA, across multiple international markets, reinforcing the company’s oncology portfolio and expansion strategy in high-growth regions.

Licensing Agreement | 17/12/2025 | By News Bureau |  161

Actimed Therapeutics Announces Licensing Agreement with Mankind Pharma

Actimed Therapeutics has entered into an exclusive licensing agreement with Mankind Pharma for S-pindolol, its novel therapy in development for cancer cachexia. The partnership marks a step toward delivering the first globally approved treatment for this debilitating condition to patients across India and South Asia.

Licensing Agreement | 21/11/2025 | By Dineshwori |  137